KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Gross Profit (2016 - 2026)

Regeneron Pharmaceuticals has reported Gross Profit over the past 18 years, most recently at $3.3 billion for Q1 2026.

  • For Q1 2026, Gross Profit rose 16.94% year-over-year to $3.3 billion; the TTM value through Mar 2026 reached $14.0 billion, up 6.84%, while the annual FY2025 figure was $13.4 billion, 2.05% up from the prior year.
  • Gross Profit for Q1 2026 was $3.3 billion at Regeneron Pharmaceuticals, down from $3.7 billion in the prior quarter.
  • Over five years, Gross Profit peaked at $3.7 billion in Q4 2025 and troughed at -$157.3 million in Q1 2022.
  • A 5-year average of $2.8 billion and a median of $3.2 billion in 2023 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: tumbled 106.71% in 2022 and later soared 2429.55% in 2023.
  • Year by year, Gross Profit stood at -$138.4 million in 2022, then soared by 2429.55% to $3.2 billion in 2023, then increased by 7.39% to $3.5 billion in 2024, then increased by 8.21% to $3.7 billion in 2025, then decreased by 11.67% to $3.3 billion in 2026.
  • Business Quant data shows Gross Profit for REGN at $3.3 billion in Q1 2026, $3.7 billion in Q4 2025, and $3.5 billion in Q3 2025.